Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2023-05-04 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim report Jan 1-Mar 31, 2023' for Vicore Pharma Holding AB. It contains comprehensive financial statements, including a summary of the period, financial overview, CEO comments, and detailed breakdowns of operating income and expenses for the first quarter. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2023
2023-05-04 English
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Vicore Pharma Holding AB (publ)" which translates to "Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)". The text details the date, time, location, prerequisites for participation, proxy rules, and the proposed agenda for the meeting. The agenda items (e.g., election of board members, approval of remuneration, authorization for share issuance) are characteristic of an AGM notice. This clearly points to a document related to the Annual General Meeting (AGM). The closest matching category is AGM Information (AGM-R). It is not a full Annual Report (10-K) or a proxy statement (PSI), but the formal notice itself.
2023-04-05 Swedish
Notice of annual general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting of Vicore Pharma Holding AB (publ)". It details the date, time, location, preconditions for participation (shareholder registration deadlines), proxy rules, proposed agenda items (including election of directors, approval of financial statements, and authorization for share issuance), and specific proposals from the nomination committee regarding board composition and remuneration. This content is characteristic of the official notice sent out to shareholders in advance of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2023-04-05 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2022 Vicore Pharma Holding AB (publ)', which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report, including a CEO comment, financial overview, management discussion, financial statements, notes, audit report, and governance report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, business strategy, clinical program updates, and detailed financial results for the fiscal year 2022. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-05 Swedish
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2022 Vicore Pharma Holding AB (publ)' and contains detailed sections typical of an annual report, including CEO comments, financial overview, pipeline details, clinical trial updates, and auditor's report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content covers the full fiscal year 2022, with comprehensive financial data and management discussion. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-05 English
Earnings Release 2022
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké 2022" (Year-End Report/Financial Statement Release 2022) and contains a detailed 'Finansiell översikt för perioden' (Financial overview for the period) covering both Q4 2022 and the full year 2022, including key metrics like Net Sales, Operating Result, Net Income, and Earnings Per Share, along with a CEO's statement and program overview. The content is comprehensive, covering operational highlights, financial results, and future outlook for the entire fiscal year. This structure strongly indicates a full annual financial report, which corresponds to the definition of a 10-K (Annual Report), even though the specific filing code '10-K' is typically used for SEC filings in the US, the content matches the definition of an Annual Report (AR/10-K). Given the comprehensive nature and year-end focus, 10-K is the most appropriate classification among the provided options for a full annual financial report. Q4 2022
2023-02-28 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.